According to FutureWise analysis the market for Continuous Renal Replacement Therapy in 2023 is US$ 1.39 billion, and is expected to reach US$ 2.48 billion by 2031 at a CAGR of 7.50%.
Rising prevalence of congestive heart failure and acute renal failure is the prime factor driving the market growth. According to the data provided by the New England Journal of Medicine, 2009, acute kidney injury has over 55% of mortality rate, resulting in the usage of renal replacement therapy. Continuous renal replacement therapy (CRRT) is primarily used for treating AKI patients that are hemodynamically unstable as it offers efficient removal of solute and a better hemodynamic stability when compared to other techniques of dialysis.
According to the data provided by Baxter,2015 the number of AKI patients across the world is predicted to reach over 1.6 million by 2020 from over 790,000 cases in 2009. Furthermore, as per the annual report of NxStage, 2013, over 190,000 acute kidney failure cases are registered in the United States alone. Moreover, as per the International Society of Nephrology, over 10% of patients hospitalised in the European Union have developed AKI with a high mortality rate. Such a high risk of AKI has significantly increased the continuous renal replacement therapy market demand. However, the high cost of CRRT is predicted to impede the market growth